Dear Reader,
The average doctor can diagnose an illness correctly 50-90% of the time.1
But one innovative company's medical AI gets it right 92%+.
The simple fact is, when it comes to many medical diagnostics, AI has already surpassed humans.
Earlier this year, an AI tool tested by the NHS caught tiny signs of breast cancer that doctors missed.2
Testing on another AI tool showed it can pick up drug interactions that humans overlook - or have never learned.3
To be clear - AI isn't going to replace your primary care physician or the ER doc.
But what AI will do is take care of some chores faster and more accurately than medical staff can.
Freeing up doctors and nurses to give each patient more time, give their treatments more attention, and eliminate all the paperwork that most medical practices are drowning in.
15%-30% of your medical bill is consumed by administrative waste, after all.4
AI can bring that number close to zero.
And the best medical AI is leading the way to this AI healthcare revolution... with the most accurate diagnostics, and a proprietary "GLM" AI platform that, unlike LLMs, has only been trained by doctors, for medical purposes.
The Bull Report
1. https://towardsdatascience.com/ai-diagnoses-disease-better-than-your-doctor-study-finds-a5cc0ffbf322. https://www.bbc.com/news/technology-68607059#:~:text=An%20AI%20tool%20tested%20by,mammograms%20of%20over%2010%2C000%20women.
3. https://www.medscape.com/viewarticle/997331?form=fpf
4. https://www.healthaffairs.org/do/10.1377/hpb20220909.830296/
This message is a paid advertisement sent on behalf of The Bull Report, a third-party advertiser of The Early Bird and MarketBeat.
This message is a paid advertisement for Treatment.com AI Inc. (CSE:TRUE, OTC:TREIF) from The Bull Report and Think Ink Marketing. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $13,500. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either The Bull Report or Think Ink Marketing. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Treatment.com AI Inc. (CSE:TRUE, OTC:TREIF) on Think Ink Marketing' website for additional information about the relationship between Think Ink Marketing and Treatment.com AI Inc. (CSE:TRUE, OTC:TREIF).
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
No comments:
Post a Comment